LSBio logo with text
Products
Research Areas
COVID-19
Resources
Contact Us
Login
Quick Order
Cart Cart lightblue
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Cart
How To Buy
Contact Us

Location

Corporate Headquarters

Vector Laboratories, Inc.
6737 Mowry Ave
Newark, CA 94560
United States

Telephone Numbers


Customer Service: (800) 227-6666 / (650) 697-3600


Contact Us


Additional Contact Details

Distributors
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order

VEGFA / VEGF

vascular endothelial growth factor A

VEGFA / VEGF is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.

Gene Name: vascular endothelial growth factor A
Family/Subfamily: PDGF , not assigned-PDGF
Synonyms: VEGFA, VPF, Vascular permeability factor, VEGF, VEGF-A, MVCD1
Target Sequences: NM_003376 NP_003367.4 P15692

Publications (22)

1
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 4:3017-24. [PubMed:9865915]
2
Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC. The Journal of pathology. 1998 186:313-8. [PubMed:10211122]
3
Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Kakolyris S, Giatromanolaki A, Koukourakis M, Leigh IM, Georgoulias V, Kanavaros P, Sivridis E, Gatter KC, Harris AL. Cancer research. 1999 59:5602-7. [PubMed:10554041]
4
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL. British journal of cancer. 2000 82:1427-32. [PubMed:10780522] [PMC:PMC2363365]
5
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Giatromanolaki A, Koukourakis MI, Sivridis E, O'Byrne K, Cox G, Thorpe PE, Gatter KC, Harris AL. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 6:1917-21. [PubMed:10815916]
6
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL. Cancer research. 2000 60:3088-95. [PubMed:10850461]
7
The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R. British journal of cancer. 2000 83:63-8. [PubMed:10883669] [PMC:PMC2374542]
8
Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Salgado R, Benoy I, Weytjens R, Van Bockstaele D, Van Marck E, Huget P, Hoylaerts M, Vermeulen P, Dirix LY. British journal of cancer. 2002 87:1437-44. [PubMed:12454774] [PMC:PMC2376277]
9
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter KC, Harris AL, Koukourakis MI. Journal of clinical pathology. 2003 56:209-13. [PubMed:12610101] [PMC:PMC1769899]
10
DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Wykoff CC, Gatter KC, Harris AL. The Journal of pathology. 2003 200:222-8. [PubMed:12754744]
11
Vascular endothelial growth factor in inflammatory bowel disease. Kapsoritakis A, Sfiridaki A, Maltezos E, Simopoulos K, Giatromanolaki A, Sivridis E, Koukourakis MI. International journal of colorectal disease. 2003 18:418-22. [PubMed:12761641]
12
Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Sivridis E. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2003 29:879-83. [PubMed:14624781]
13
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F. British journal of cancer. 2005 92:94-101. [PubMed:15558070] [PMC:PMC2361752]
14
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 10:7965-71. [PubMed:15585631]
15
Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD. Molecular cancer research : MCR. 2008 6:352-63. [PubMed:18337445] [PMC:PMC2442564]
16
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Abdeen A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, Kim M, Wang D, Moody K, Gorlick R. Cancer. 2009 115:5243-50. (IHC-P; Human) [PubMed:19670450]
17
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, Andr V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 17:6582-91. [PubMed:21831956]
18
ß-Cell regeneration mediated by human bone marrow mesenchymal stem cells. Milanesi A, Lee JW, Li Z, Da Sacco S, Villani V, Cervantes V, Perin L, Yu JS. PloS one. 2012 7:e42177. (ICC, IHC; Mouse) [PubMed:22879915] [PMC:PMC3413696]
19
Gene expression of vascular endothelial growth factor A and hypoxic adaptation in Tibetan pig. Zhang B, Qiangba Y, Shang P, Lu Y, Yang Y, Wang Z, Zhang H. Journal of animal science and biotechnology. 2016 7:21. (WB; Porcine) [Full Text Article] [PubMed:27042296] [PMC:PMC4818941] Related Antibodies: LS-C2929.
20
Attenuation of Post-Traumatic Osteoarthritis After Anterior Cruciate Ligament Injury Via Inhibition of Hedgehog Signaling. Shinichiro Takada, Eiichiro Nakamura, Ken Sabanai, Manabu Tsukamoto, Hajime Otomo, Shinkichi Kanoh, Teppei Murai, Hokuto Fukuda, Yasuaki Okada, Soshi Uchida, Akinori Sakai. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2020 March;38:609-619. [Full Text Article] [PubMed:31608494]
21
Short communication: Adipocyte sizes in the digital fat pad and their relationship to body condition in dairy cows. S Hiss-Pesch, J Weise, B Heitkönig, H Sauerwein. Journal of dairy science. 2019 July;102:6551-6554. [Full Text Article] [PubMed:31056330] Related Antibodies: LS-C2929.
22
Rosmarinic acid prevents post-operative abdominal adhesions in a rat model. Ali Kakanezhadi , Mehrdad Rezaei , Abbas Raisi, Omid Dezfoulian, Farshid Davoodi, Hassan Ahmadvand. Scientific reports. 2022 November;12:18593. [Full Text Article] [PubMed:36329196] [PMC:PMC9633689] Related Antibodies: LS-B7747.
more

☰ Filters
Products
Proteins (54)
Over-Expression Lysate (7)
Recombinant (47)
VEGFA / VEGF (54)
No (54)
6His, C-terminus (2)
6His, N-terminus (1)
GST (1)
GST, N-terminus (1)
His (12)
His, N-Terminal (6)
His-GST (1)
His-SUMO (1)
His-T7 (2)
Myc-DDK (Flag) (7)
Bovine (2)
Dog (1)
Human (25)
Mouse (8)
Pig (3)
Rabbit (3)
Rat (8)
Rhesus monkey (1)
293F Cells (2)
293T Cells (4)
Baculovirus (1)
E. coli (30)
HEK 293 Cells (4)
Human Cells (2)
Mammalian Cells (2)
Pichia pastoris (1)
Wheat Germ Extract (2)
Yeast (6)
Purified (15)
Low endotoxin level (20)
Biologically active (10)
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A (VEGFA) by SDS-PAGE
Select
Rhesus monkey VEGFA / VEGF Protein (Recombinant His, N-Terminal) (Pro20-Arg224) - LS-G132674
E. coli
His, N-Terminal
25.1kDa
10 µg/$295; 50 µg/$532; 200 µg/$1,049; 100 µg/$850; 1 mg/$2,215; 500 µg/$1,733; 5 mg/$3,711; 2 mg/$2,407
Select
Rabbit VEGFA / VEGF Protein (Recombinant His) (aa51-511) - LS-G23186
Yeast
His
51.7 kD
1 mg/$1,973; 100 µg/$679; 20 µg/$429
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A By SDS-PAGE
Select
Rat VEGFA / VEGF Protein (Recombinant His) (aa27-190) - LS-G11695
E. coli
His
20.8 kDa
10 µg/$287; 50 µg/$482; 100 µg/$770; 200 µg/$962; 1 mg/$2,094; 500 µg/$1,623; 5 mg/$3,361; 2 mg/$2,284
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A By SDS-PAGE
Select
Rabbit VEGFA / VEGF Protein (Recombinant His-T7) (aa1-120) - LS-G11693
E. coli
His-T7
17.9 kDa
10 µg/$287; 50 µg/$482; 100 µg/$770; 200 µg/$962; 1 mg/$2,094; 500 µg/$1,623; 5 mg/$3,361; 2 mg/$2,284
VEGFA / VEGF Protein
Select
Human VEGFA / VEGF Protein (Recombinant) - LS-G1691
E. coli
None
50 µg/$411; 250 µg/$985; 10 µg/$276
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A By SDS-PAGE
Select
Pig VEGFA / VEGF Protein (Recombinant His-GST) (aa27-190) - LS-G11691
E. coli
His-GST
51.2 kDa
10 µg/$287; 50 µg/$482; 100 µg/$770; 200 µg/$962; 1 mg/$2,094; 500 µg/$1,623; 5 mg/$3,361; 2 mg/$2,284
VEGFA / VEGF Protein
Select
Human VEGFA / VEGF Protein (Recombinant) - LS-G515
E. coli
None
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
100 µg/$361; 500 µg/$739; 20 µg/$261
Select
Rat VEGFA / VEGF Protein (Recombinant) (Ala27-Arg190) - LS-G40054
Yeast
None
Less than 1.0 EU/µg protein (determined by LAL method).
19.2kD
10 µg/$297; 50 µg/$468; 500 µg/$1,585; 1 mg/$2,157
Select
Mouse VEGFA / VEGF Protein (Recombinant) - LS-G131556
E. coli
164 AA
None
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
~19.6 kDa
10 µg/$258; 100 µg/$698; 1 mg/$1,891
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A By SDS-PAGE
Select
Dog VEGFA / VEGF Protein (Recombinant His, N-Terminal) (aa27-190) - LS-G11692
E. coli
His, N-Terminal
19.1 kDa
10 µg/$307; 50 µg/$602; 100 µg/$962; 200 µg/$1,156; 1 mg/$2,369; 500 µg/$1,876; 5 mg/$4,201; 2 mg/$2,562
VEGFA / VEGF Protein
Select
Human VEGFA / VEGF Protein (Recombinant His) - LS-G3095
Baculovirus
His
20 µg/$361; 100 µg/$739; 4 µg/$261
Select
Human VEGFA / VEGF Protein (Recombinant) (aa27-191) - LS-G5808
E. coli
None
Biologically active
38.6 kDa
10 µg/$388; 100 µg/$1,186; 500 µg/$2,269
VEGFA / VEGF Protein
Select
Human VEGFA / VEGF Protein (Recombinant) (aa27-191) - LS-G5895
Yeast
None
Biologically active
20-31 kDa
10 µg/$388; 100 µg/$1,186; 500 µg/$2,269
Select
Human VEGFA / VEGF Protein (Recombinant) (Ala27-Arg191) - LS-G38624
Human Cells
None
Less than 1.0 EU/µg protein (determined by LAL method).
19.1kD
10 µg/$321; 50 µg/$534; 500 µg/$1,716; 1 mg/$2,451
Select
Human VEGFA / VEGF Protein (Recombinant) (Ala27-Arg147) - LS-G39145
E. coli
None
Less than 1.0 EU/µg protein (determined by LAL method).
14.2kD
10 µg/$321; 50 µg/$534; 500 µg/$1,585; 1 mg/$2,353
Select
Human VEGFA / VEGF Protein (Recombinant 6His, C-terminus) (Ala27-Arg147) - LS-G39140
Human Cells
6His, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
15.1kD
10 µg/$321; 50 µg/$534; 500 µg/$1,585; 1 mg/$2,353
VEGFA / VEGF Protein - 12.5% SDS-PAGE of human VEGFA stained with Coomassie Blue
Select
Human VEGFA / VEGF Protein (Recombinant GST) (Full Length) - LS-G30873
Wheat Germ Extract
GST
43.6 kDa
10 µg/$479; 25 µg/$670
VEGFA / VEGF Protein - 12.5% SDS-PAGE Stained with Coomassie Blue.
Select
Human VEGFA / VEGF Protein (Recombinant GST, N-terminus) (aa27-130) - LS-G60508
Wheat Germ Extract
GST, N-terminus
10 µg/$479; 25 µg/$670
VEGFA / VEGF Protein
Select
Human VEGFA / VEGF Protein (Recombinant His, N-Terminal) (Ala27-Arg191) - LS-G96950
HEK 293 Cells
His, N-Terminal
~19 kDa (22-30 kDa reducing conditions)
10 µg/$289; 100 µg/$432; 50 µg/$360
VEGFA / VEGF Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
Human VEGFA / VEGF Protein (Over-Expression Lysate Myc-DDK (Flag)) (Full Length) - LS-G81273
293T Cells
Myc-DDK (Flag)
45.3 kDa
20 µg/$150
Select
Human VEGFA / VEGF Protein (Over-Expression Lysate Myc-DDK (Flag)) (Full Length) - LS-G81274
293T Cells
Myc-DDK (Flag)
45.3 kDa
20 µg/$150
VEGFA / VEGF Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
Human VEGFA / VEGF Protein (Over-Expression Lysate Myc-DDK (Flag)) (Full Length) - LS-G81276
293T Cells
Myc-DDK (Flag)
35.5 kDa
20 µg/$150
VEGFA / VEGF Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
Human VEGFA / VEGF Protein (Over-Expression Lysate Myc-DDK (Flag)) (Full Length) - LS-G81279
293T Cells
Myc-DDK (Flag)
40.5 kDa
20 µg/$150
VEGFA / VEGF Protein - Western validation with an anti-DDK antibody * L: Control HEK293 lysate R: Over-expression lysate
Select
VEGFA / VEGF Protein (Over-Expression Lysate Myc-DDK (Flag)) (Full Length) - LS-G120964
HEK 293 Cells
Myc-DDK (Flag)
40.5 kDa
100 µg/$494
Select
Human VEGFA / VEGF Protein (Recombinant) (Ala27-Arg147) - LS-G140455
E. coli
None
Less than 1.0 EU/µg protein (determined by LAL method).
14.2 kDa
20 µg/$360; 100 µg/$728
Viewing 1-25 of 54 product results

(0) Selected Add Selected To Cart Compare Selected Clear Selected Top Of Search
Filtered By:
Products: Proteins


If you do not find the reagent or information you require, please contact Customer.Support@LSBio.com to inquire about additional products in development.

PLEASE NOTE

For RESEARCH USE ONLY. Intended for use by laboratory professionals. Not intended for human diagnostic or therapeutic purposes.

The data on this page has been compiled from LifeSpan internal sources, the National Center for Biotechnology Information (NCBI), and The Universal Protein Resource (UniProt).

Family of Companies
Site Links Home All Antibodies How To Buy All Proteins Distributors All ELISA & Assay Kits Reviews PathPlus™ Antibodies
Follow LSBio View Cart Register or Login
Copyright © 2024 LifeSpan BioSciences, Inc - Privacy Policy
Contact Us

Vector Laboratories, Inc.
6737 Mowry Ave
Newark, CA 94560
United States

Tel: (800) 227-6666 / (650) 697-3600

To place an order:
customerservice@vectorlabs.com

For questions about orders:
Customer.Support@LSBio.com

For technical assistance:
Technical.Support@LSBio.com